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Human in-vivo 31P MR Spectroscopy 
of Benign and Malignant Breast Tumors 
Objective: To assess the potential clinical utility of in-vivo 31P magnetic reso-
nance spectroscopy (MRS) in patients with various malignant and benign breast
lesions.
Materials and Methods: Seventeen patients with untreated primary malignant
breast lesions (group I), eight patients with untreated benign breast lesions
(group II) and seven normal breasts (group III) were included in this study. In-vivo
31P MRS was performed using a 1.5 Tesla MR scanner. Because of the charac-
teristics of the coil, the volume of the tumor had to exceed 12 cc (3 2
2 cm), with a superoinferior diameter at least 3 cm. Mean and standard devia-
tions of each metabolite were calculated and metabolite ratios, such as PME/PCr,
PDE/PCr, T-ATP/PCr and PCr/T-ATP were calculated and statistically analyzed. 
Results: Significant differences in PME were noted between groups I and III
(p=0.0213), and between groups II and III (p=0.0213). The metabolite ratios
which showed significant differences were PME/PCr (between groups II and III)
(p=0.0201), PDE/PCr (between groups I and III, and between groups II and III)
(p=0.0172), T-ATP/PCr (between groups II and III) (p=0.0287), and PCr/T-ATP
(between groups II and III) (p=0.0287). There were no significant parameters
between groups I and II. 
Conclusion: In-vivo 31P MRS is not helpful for establishing a differential diag-
nosis between benign and malignant breast lesions, at least with relatively large
lesions greater than 3 cm in one or more dimensions. 
R spectroscopy (MRS) has been used in the diagnosis and characteriza-
tion of many disease processes, including breast diseases, as a noninva-
sive method which can provide in-vivo data on human biochemistry and
pathophysiology. 1H, 13C, 14N, 19F, 23Na and 31P have been used in MRS (1, 2),
1H and 31P being used most widely. 31P MRS is especially suitable for breast studies,
more so than 1H because water suppression is not essential and there is a relative lack
of phosphorus metabolites in normal breast tissue (3). The use of 31P MRS for brain,
heart, muscle and liver studies (1, 4 5), as well as for diagnosing breast diseases (3, 6
25), has already been reported in the literature. However, the results have varied be-
cause of differences in the design, materials, and methods of the various studies. 
Our study was undertaken to assess the potential clinical utility of in-vivo 31P MRS
in the diagnosis of various untreated primary malignant and benign human breast le-
sions compared to normal tissue. For all lesions, study conditions were the same, in-
cluding the use of a large volume of solid tissue in order to avoid contamination from
adjacent tissue.
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Seventeen patients with malignant lesions [Group I;
mean age of patients, 41.1 (range, 24 62) years], eight with
benign lesions [Group II; mean age, 32.1 (range, 19 44)
years] and, as controls, seven normal breasts [Group III;
mean age, 43.7 (range, 40 47) years] were included.
Patients with a palpable mass who had not previously un-
dergone treatment or surgery were selected, and 18, fine
needle aspiration biopsy (FNAB) was followed by 31P
MRS between one day and eight months later. All malig-
nant lesions were primary breast malignancies and in 12
patients (66.7%), the results of FNAB and surgical histol-
ogy were consistent. Because of the characteristic of the
coil, the volume of the tumor had to exceed 12 cc (3 2
2 cm), with a superoinferior diameter at least 3 cm, and ei-
ther for this reason or because of the long interval between
FNAB and 31P MRS, the effect of FNAB on 31P MRS was
neglected. 
Malignant tumors in which possible internal hemorrhage
or necrosis had been revealed by previous clinical or radio-
logical examination were excluded. Modified radical mas-
tectomy was performed in 14 patients, one underwent
lumpectomy, and because of metastasis, two were treated
with chemotherapy only. Final pathologic diagnoses were
invasive ductal carcinoma (n=14), medullary carcinoma
(n=1), mucinous carcinoma (n=1), and metaplastic carcino-
ma, matrix-producing type (n=1).
Seven patients with benign lesions underwent excisional
biopsy, and because a huge benign phyllodes tumor was
present, the other underwent modified radical mastectomy.
Final pathologic diagnoses were fibroadenoma (n=4), be-
nign phyllodes tumor (n=2), lactating adenoma (n=1), and
fibrocystic change (n=1). Five healthy women without any
history of previous breast disease were selected as controls
and the contralateral normal breasts of two patients with
invasive ductal carcinoma were also included in this group.
To confirm the normalcy of the breast as well as the appro-
priateness of the amount of breast tissue, mammography
was performed prior to MRS. The menstrual cycle was in
the luteal phase in two patients and in the menstrual phase
in one; three had ceased to menstruate because of previous
hysterectomy, chemotherapy or recent hormone replace-
ment therapy, and one did not recall the date of her last
menstruation. Verbal consent was obtained from all pa-
tients prior to examination. 
One patient underwent 31P MRS prior to chemotherapy
and three more times during chemotherapy. 
All studies were performed consecutively between
January 1999 and March 2000, and the project was ap-
proved by our institutional review board.
Methods
MRS was performed not more than a week prior to
surgery, chemotherapy or any other treatment. For all ex-
aminations, a 1.5T whole-body MRI/MRS system (1.5 T
Magnetom Vision ; Siemens, Erlangen, Germany) with a
1H 31P dual surface coil (27 cm 14 cm loops with 1H exci-
tation and signal detection and 31P signal detection with a
31P preamplifier) was used. Patients were positioned ei-
ther supine or prone on the table, with the 1H-31P dual
surface coil covering the area of the tumor. The findings of
previous mammographic and/or ultrasonographic studies
were reviewed prior to and while MRS was being per-
formed, and T1-weighted localizer MR images were ob-
tained (TR 300 ms, TE 12 ms, 5 mm slice thickness, 420
mm field of view, 154 256 acquisition matrix, 2 NEX of
acquisition). Localization was readjusted several times until
the center of the coil correlated well with the center of the
tumor. In each case approximately 15 minutes were need-
ed to obtain the 31P MR spectrum, and spectral parame-
ters were as follows : TR 330 ms, TE 3 ms, flip angle 90 ,
slab thickness 50 mm, FOV 420 mm, 16 1024 acquisition
matrix, 11 NEX of acquisition.
Raw data (the integral of each metabolite) were obtained
after the completion of scan averages for each examination
and transferred to an installed program (Numaris spec-
troscopy analysis package VB33A). Apodization, zero- and
first-order phase corrections were performed and all 31P
MR spectra were plotted and analyzed in the absorption
mode and then fitted to Lorentzian lineshapes. 31P MR
resonances in the spectra were assigned on the basis of pri-
or assignments such as phosphocreatine (PCr), inorganic
phosphate (Pi), phosphomonoester (PME), phosphodiester
(PDE), and  ,  and  phosphorus adenosine triphosphate
(ATP). Chemical shifts in 31P MR spectra were referenced
to the position of PCr ( =0.0 ppm) (PME, 7.1 ppm ;
Pi, 5.3 ppm ; PDE, 3.6 ppm,  -phosphorus of ATP, -2.4
ppm ;  -phosphorus of ATP, -7.7 ppm ; and  -phosphorus
of ATP, -16.1 ppm) (13). 
For normal controls, the coil was located in the area of
the largest amount of normal tissue, which was most often
2 cm above and away from the nipple. The right breast
was preferred because of the artifact from the heartbeat
which occurs with the left breast.
Analysis of raw data 
Mean and standard deviations of the integral of each
metabolite were measured (Table 1). Various metabolite
ratios were obtained, namely PME/PCr, Pi/PCr, PDE/PCr,
-ATP/PCr,  -ATP/PCr,  -ATP/PCr, T-ATP/PCr, PME/ -
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ATP/ -ATP, T-ATP/ -ATP, PME/T-ATP, Pi/T-ATP,
PDE/T-ATP, PCr/T-ATP,  -ATP/T-ATP,  -ATP/T-ATP,  -
ATP/T-ATP, and PDE/PME. Data for the three groups
were analyzed and compared using the Kruskal-Wallis test
with Dunn’s method; a p level of less than 0.05 was consid-
ered significant.
RESULTS
Seven parameters were statistically significant (Table 2).
PME was significantly higher in both malignant and benign
lesions than in normal tissue. PDE/PCr was also significant-
ly different in both malignant and benign lesions compared
to normal tissue, a finding which resulted from the relative-
ly high PDE and low PCr in malignant and benign lesions
and the relatively high PCr and low PDE in normal tissue.
PME/PCr, T-ATP/PCr and PCr/T-ATP showed significant
differences between benign lesions and normal tissue be-
cause of relatively high PME and T-ATP and low PCr in
benign lesions and relatively low PME and T-ATP and high
PCr in normal tissue. Differences between malignant le-
sions and normal tissue were borderline, and those be-
tween malignant and benign lesions were not significant.
One patient who underwent four consecutive 31P MRS
scans before and after chemotherapy showed elevated PCr
and decreased PDE and PME when her clinical response to
this therapy was good, and elevated PDE and decreased
PCr when her response was poor (Table 3). This patient
had lung metastasis, and clinical response was assessed ac-
cording to her general condition, as indicated by blood
markers and laboratory tests, and by the softness of the tu-
mor on palpation. Magnetic resonance imaging (MRI) dur-
ing chemotherapy revealed little apparent change in the
size of her tumor or the extent of intratumoral microcali-
fication (Fig. 1 4).
DISCUSSION
Phosphorus metabolites play an important role in the hu-
man body as high energy metabolites. Phosphorus is fun-
damental for obtaining information about cell energy me-
tabolism, the state of tissue oxygenation, pH, and mem-
brane turnover (1). Phosphorus metabolites are abundant
in viable tissue, and their clear, wide chemical shift spec-
trum observed in MRS; recommends them for use in medi-
cine. The concentration of phosphorus metabolites is only
one-tenth that of proton, however, and their signal is
100,000 times weaker than that of hydrogen (1, 3), and
thus the clinical usefulness of 31P MRS is limited. It is,
nonetheless, more suitable than other alternatives in set-
tings involving the breast: this is a superficial organ, water
suppression is not essential, and there is a greater lack of
phosphorus metabolites in normal breast tissue than in oth-
Park et al.
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Table 1. Mean Peak Areas of Phosphorus Metabolites ( standard deviation) of Malignant Breast Lesions (n=17), Benign
Breast Lesions (n=8) and Normal Breast Tissue (n=7).
Phosphorus metabolites Malignant lesions (n=17) Benign lesions (n=8) Normal tissue (n=7)
Mean SD Mean SD Mean SD
PME 138.36 088.83 153.38 092.7700 48.27 37.06
Pi 127.41 075.58 121.43 082.0900 91.73 35.87
PDE 279.23 256.93 233.98 148.9300 96.86 58.41
PCr 125.86 099.28 104.39 097.100 171.47 78.07
-ATP 090.40 051.40 108.13 028.7000 70.52 31.79
-ATP 106.70 051.26 100.98 066.9400 66.41 23.01
-ATP 091.98 037.20 089.29 048.6400 67.87 36.37
T-ATP 289.08 109.54 298.39 132.990 204.79 69.57
Note.─ PME, phosphomonoester; Pi, inorganic phosphate; PDE, phosphodiester; PCr, phosphocreatine;  -ATP,  -adenosine triphosphate;  -ATP,  -
adenosine triphosphate;  -ATP,  -adenosine triphosphate; T-ATP, total adenosine triphosphate ( -ATP +  -ATP +  -ATP); SD, standard deviation.
Table 2. Metabolite Ratios with Significant Differences
between Malignant Breast Lesions (Group I),
Benign Breast Lesions (Group II), and Normal
Breast Tissue (Group III).
Metabolite ratios
Groups (p-value)
I vs. II I vs. III II vs. III
PME NS S (0.0213) S (0.0213)
PME/PCr NS NS  S (0.0201)
PDE/PCr NS S (0.0172) S (0.0172)
T-ATP/PCr NS NS S (0.0287)
PCr/T-ATP NS NS S (0.0287)
Note.─ NS, not significant; S, significant; PME, phosphomonoester;
PCr, phosphocreatine; PDE, phosphodiester; T-ATP, total adenosine
triphosphate ( -ATP +  -ATP +  -ATP).er normal tissue (3, 5). 
Among the seven peaks of phosphorus metabolites in
31P MRS, a high energy phosphate such as PCr or ATP
provides energy for cytologic metabolites, and Pi repre-
sents the lowest energy state which increases in concentra-
tion as tissue becomes ischemic (1). PME indicates the
presence of precursors of cytoplasmic membrane biosyn-
thesis, such as phosphoethanolamine (PE) and phospho-
choline (PC). PDE indicates the presence of breakdown
products of membrane metabolism, such as glycerophos-
phoethanolamine and glycerophosphocholine (GPC). 
Most tumors in organs such as the liver, brain and muscle
show decreased PCr and increased PME and PDE, with
greater change in PME (2). An elevated PME level reflects
the higher membrane phospholipid metabolism associated
with higher tumor cell reproduction and growth rates (2),
though its level does not actually appear to correlate with
the degree of malignancy. A good treatment response is in-
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Table 3. Mean Peak Areas of Phosphorus Metabolites in Invasive Ductal Carcinoma before and after Chemotherapy in a
Patient Who Underwent Three Consecutive 31P MRS Sessions During Chemotherapy .
Phosphorus metabolites Mean peak areas
Before chemotherapy After chemotherapy F/U I After chemotherapy F/U II  After chemotherapy F/U III
PME 358.83 092.43 206.78 101.84
Pi 318.96 186.77 136.79 113.01
PDE 746.24 121.26 356.57 081.44
PCr 308.42 165.65 178.01 170.99
-ATP 214.60 80.38 082.62 041.09
-ATP 186.95 113.11 162.08 106.49
-ATP 177.18 146.39 055.58 068.33
T-ATP 578.73 339.88 300.28 215.91
Note.─ F/U I, II, III: first, second and third follow-up; PME, phosphomonoester; Pi, inorganic phosphate; PDE, phosphodiester; PCr, phosphocreatine;  -
ATP,  -adenosine triphosphate;  -ATP,  -adenosine triphosphate;  -ATP,  -adenosine triphosphate; T-ATP, total adenosine triphosphate ( -ATP +  -
ATP +  -ATP)
F/U I was performed after four chemotherapy sessions during which the patient showed a very good clinical response. F/U II took place after six
chemotherapy sessions during which the patient’s status was aggravated. F/U III was performed after eight chemotherapy treatments, at which time the
patient again showed a positive clinical response. 
Fig. 1. 31P MRS of a 27-year-old patient with invasive ductal car-
cinoma of the breast. Among the seven phosphate metabolites,
PDE shows the highest level (644.77) and PCr is low (48.34).
Arrows indicate the mentioned values.
Fig. 2. 31P MRS of a 38-year-old patient with benign phyllodes
tumor. Among the seven phosphate metabolites, PDE shows the
highest level (682.13) and PCr is low (83.47). Arrows indicate the
mentioned values.dicated by decreased PME and PDE levels and increased
PCr (15 17), while a poor response results in increased
PME (17). These changes do not correlate with volume
change, i.e. they are changes detectable by MRS before
any detectable change in tumor volume. In our study, a pa-
tient who underwent four consecutive 31P MRS scans be-
fore and after chemotherapy showed elevated PCr and de-
creased PDE and PME at the time her clinical response was
good. Because the MRI findings showed little changeduring
the same period, these findings were important. 
The current literature regarding 31P MRS of the breast
describes variations in normal breast tissue according to
the menstrual cycle, lactation, and the presence of various
carcinomas, as determined by in-vivo, ex-vivo and in-vitro
methods. Merchant et al. (13) reported that PME+Pi were
lower and PDE+phosphorylated glycan (PG) were higher
in breast cancers than in normal tissue and that PCr was
high in benign disease, and Merchant (3) noted similar
findings, namely that PME and Pi were lower and PDE and
phosphorylated glycan were higher in breast cancers than
in normal tissue. Redmond et al. (18) reported that  -ATP
and  -ATP were high and PCr was low in carcinomatous
tissue, but that PCr was high in normal tissue. PDE/PCr
was high in carcinomatous tissue, but this was without sta-
tistical significance. 
Smith et al. (19) demonstrated low glycerophospho-
rylethanolamine levels, and low NTP and high Pi, in 46 hu-
man breast ductal carcinoma extracts. Degani et al. (20)
documented the presence of increased NTP/Pi after tamox-
ifen treatment, as revealed by 31P MRS scanning of breast
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Fig. 4. A. 31P MRS of a 43-year-old patient with invasive ductal carcinoma of the breast prior to chemotherapy. Note the high levels of
PME (358.83) and PDE (746.24) and the relatively low PCr level (308.42). 
B. Follow-up MRS after chemotherapy. The PCr level is relatively high (165.65), and PME and PDE levels are lower than in the previous
study, i.e. 92.43 and 121.26, respectively. Arrows indicate the mentioned values.
AB
Fig. 3. 31P MRS of a 41-year-old normal volunteer. Note the
highest peak of PCr (247.53). An arrow indicates the mentioned
value.cancer tissue using the human MCF7 breast cancer cell line
in athymic mice. This increase was explained as resulting
from the rapid growth of fibrous reparative tissue follow-
ing rapid necrosis. Singer et al. (21) obtained 31P MRS
scans of breast cancer cell lines such as primary breast car-
cinoma (21PT, 21NT), metastatic breast carcinoma (21MT-
2), and normal epithelium of the breast (76N); their results
showed a 16 27-fold increase in phosphocholine (PC) in
primary and metastatic carcinomas and decreased ATP and
PCr, suggesting that the mechanism involved in the
marked increase in PC was actually increased PC synthe-
sis, or its decreased use in carcinomatous tissue. Using tis-
sue extracts, Merchant et al. (22) showed that 31P MRS
could differentiate benign from malignant lesions on the
basis of elevated PME, and by the use of biopsy samples,
Degani et al. (24) demonstrated that carcinomas contain
three times more ATP and PME than benign breast lesions.
Sijen et al. (15) performed in-vivo 31P MRS scanning in
five human breast carcinoma patients and four normal vol-
unteers, finding that in carcinomatous tissue there was high
PME, Pi and PDE, but little PCr. PME decreased and PCr
increased following radiotherapy, while in normal volun-
teers, PCr was high and all other phosphate metabolites
were low. Kalra et al. (14) performed in-vivo 31P MRS
scanning in 31 cases of human breast carcinoma, finding
that PME and PDE were high but that PCr was not detect-
ed. In 14 normal volunteers, all phosphate metabolite lev-
els were very low, and in three elderly patients undergoing
tamoxifen therapy, PME/ -ATP decreased with clinical im-
provement and increased when there was no improve-
ment. Twelves et al. (16) performed in-vivo 31P MRS in
23 human breast carcinomas, finding high levels of PME,
PDE and PCr, and low ATP. The results also revealed in-
creased PCr and decreased PME levels after chemothera-
py. Merchant et al. (25) demonstrated significant differ-
ences in PCr/Pi levels in both malignant and benign le-
sions, explaining that if parallel to ATP/Pi, this difference
indicated necrosis of tumor tissue before volume changes
occurred. Our study included only solid lesions without
necrosis and no parameters were able to significantly dif-
ferentiate malignant from benign lesions. 
Among 46 normal volunteers, Redmond et al. (18) found
higher PME and ATP levels and lower PCr in pre-
menopausal than in postmenopausal women, while in their
five normal volunteers, Sijen et al. (15) found elevated PCr
and low levels of all phosphate metabolites (PME, Pi, PDE,
and ATP). Twelves et al. (23) reported the results of in-vi-
vo 31P MRS studies in eight lactating women and 14 non-
lactating premenopausal women. The high levels of PME
found among the former probably reflected the higher pro-
portion of epithelial tissue present during lactation. PCr
was low in these same women, and lowest during the fol-
licular phase in normal premenopausal women. 
The use of many metabolite ratios was inevitable be-
cause the quantitation of 31P suffers limitations arising
from many factors. These include the difficulty of appro-
priate calibration, the sensitivity of surface coils, and tech-
nical variations in the geometry of many of the localization
techniques and the minimization of noise differences (1,
18). Also, because the intensity of PME and PDE is low,
analysis of their levels is difficult (2). Sijens et al. (15) used
the PCr/ATP ratio, but other researchers used different ra-
tios such as PM/ATP (2), PME/ -ATP and PDE/ -ATP
(14), PME+Pi and PDE+PG (17), PDE/PCr, ATP/PCr and
Pi/PDE (18), the percentage of the total 31P peak area of
the spectrum, PDE/PME and PCr/Pi (16, 23), and PME/Pi,
ATP/Pi, PCr/Pi, PME/ATP, PCr/ATP, PCr+Pi/ATP, glyc-
erol phosphodiesters(GPD)/ATP and PDE/ATP (24). No
concensus as to the most useful of these has emerged. 
The diversity of the results reported in the literature
seems to have numerous causes. Tumors before and after
treatment, for example, and those with a large amount of
necrosis were included in the same group, yet comparisons
with benign lesions or normal volunteers were not made
(5, 15, 19). In other cases, normal parenchymal tissue or
pectoralis muscle was included in the area of examination
(13-16, 18), or the diverse spectrum of benign diseases
from cyst to fibroadenoma was included in the same group
(24). In our study, in order to avoid contamination and in-
clude tumor tissue only, at least 12 cc of solid tumor with-
out necrosis or hemorrhage was selected. As well as nor-
mal thissue, malignant and malign lesions were also includ-
ed. 
According to the literature, metabolite ratios for benign
lesions differ from those for malignant tissue and are not
distinguishable from those for normal breast tissue (1, 3,
15, 18, 22, 24, 25). In our study, PME, PDE and PCr levels
in cancers and normal tissue were similar to those previ-
ously reported. Although the menstrual phases of normal
control subjects varied, the patterns were all similar;
among phosphorus metabolites, PCr showed the highest
levels, and PME and PDE the lowest. In this study, howev-
er, benign and malignant lesions could not be differentiat-
ed. Because we included only large lesions, those with a
volume of at least 12 cc, an explanation for this result
could be that for large lesions, whether pathologically be-
nign or malignant, tumor metabolism is similar. The litera-
ture explains that lactating breasts show a similar spectral
pattern to that of malignant lesions (16, 23), the suggested
mechanisms for this being either that 1) PME simply re-
flects the increased proportion of epithelial tissue, whether
normal or malignant, or 2) that elevated PME may be due
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to increased membrane synthesis in hyperplastic or prolif-
erating breast tissue (16). That all patients involved in this
study were relatively young is probably related to the fact
that among Korean women, the age at which breast cancer
is most prevalent is about ten years less than among west-
ern women. The reason for this is not clear. 
In conclusion, localized in-vivo 31P MRS in the present
study showed that using current techniques, a broad clini-
cal spectrum can be demonstrated. In addition, and con-
trary to the conclusions reached by earlier reports, 31P
MRS does not in fact differentiate malignant from benign
breast lesions, at least where the volume of a lesion is rela-
tively large. Although not statistically proven in this study,
the primary role of 31P MRS in breast disease may, there-
fore, be to monitor the response of sizable tumors during
therapeutic trials rather than the differential diagnosis of
benign from malignant lesions or the initial diagnosis of
small, early breast cancer. 
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